Introduction

Cell and Gene therapies represent one of the most transformative areas of modern medicine. However, despite their clinical promise, the manufacturing and operational model remains fundamentally artisanal. Production processes are frequently characterized by manual handling, fragmented workflows, and limited automation, making scale-up difficult and costly. Maturity of most supply chains frameworks and integrated business planning processes are still in its infancy for the industry.

This gap between scientific innovation and operating at a true industrial manufacturing and geographic scale has emerged as one of the principal constraints on the widespread availability of these therapies. The sector therefore is entering a structural inflection point. Scientific breakthroughs made advanced therapies possible. Fully working operational value chain models will determine how far they scale. We believe the future will be defined not by whom builds the most capacity, but by whom designs the most resilient and coordinated operational value chain to deliver it.

Upcoming regulatory approvals, a growing number of start-ups and clinical trials, novelty modalities, indication broadening, earlier-line approvals and maturing treatment networks are all factors driving throughput levels approaching — and in some cases already planning for — 10,000 patient-specific batches per year.

Clinical success creates opportunity. Operational excellence and cost control determine enterprise value and long-term reliable supply to patients in need. Industrial leadership is not simply about building more. It is about building at the right time.

---

The Structural Difference in Autologous Manufacturing

At first glance, scaling appears to be a question of infrastructure: more suites, more vector capacity, larger QC laboratories, expanded logistics contracts and so on. Yet our modelling and operational analysis suggest that capacity alone will not determine success at industrial scale.

Let’s get into some more details and examples.

Autologous manufacturing does not scale like conventional biologics. As we know, each batch is tied to a single patient. There is no interchangeable, off the shelf, finished goods inventory. Apheresis scheduling, manufacturing planning, sterility release, infusion and reimbursement are temporally and economically linked. Other challenges in managing this integrated and complex model are abundant. A key example is regulatory gating — most notably the14–15-day sterility incubation time which imposes a deterministic time floor that cannot be compressed through effort or overtime. This example alone easily creates a conflict between QA/QC and patient urgency. At modest volumes, such constraints and complexities are manageable through programme-level coordination. At industrial volumes, they interact in ways that produce systemic fragility, a so a new fully operational framework needs to be designed, implemented and operated.

In our detailed modelling under the feasibility study “RESYNC-SC Systemic Orchestration in Distributed, Multi-Asset Autologous CAR-T Manufacturing: An Industrial-Scale Feasibility Analysis Across EU–US Networks” of a distributed EU–US network at 10,000 annual batches, manufacturing suites operated at what most industrial leaders would consider efficient utilisation levels — roughly 86–90%. On paper, the system appeared well-sized. Yet instability and bottlenecks did not originate in manufacturing absolute capacity and process control. It emerged in Quality Control and Operational Excellence.

Let’s continue.

---

The Often-Invisible Scaling Ceiling: QC Sterility Gating

Sterility testing introduces a non-negotiable release floor and hence the most direct impact on the overall Vein to Vein timeline. When throughput increases and QC utilisation approaches the 92–95% band, waiting times escalate non-linearly. This is not a gradual degradation; it is a tipping dynamic. Under baseline assumptions, average QC waiting times extended-release timelines by approximately three days beyond sterility incubation. That delay may appear operationally tolerable in isolation. However, when multiplied across 10,000 annual batches, it resulted in effective slot loss of over 7%.

Slot loss is rarely visible in capacity dashboards or at least it does not appear as a catastrophic failure. Instead, it manifests as rescheduling, micro-delays, and ripple effects upstream across logistics, manufacturing and infusion planning. Economically, however, it is material. At industrial scale, a 7% slot loss translated into nearly $28,000 additional cost per batch and more than $250 million in annual inefficiency. In price-sensitive reimbursement regions such as parts of Europe, that degree of inefficiency could erode contribution margin (revenue – variable costs) entirely!

When demand increased by just 10%, QC utilisation crossed a structural stability threshold. Waiting times doubled, slot loss exceeded 12%, and expansion triggers were activated — not because the network lacked nominal capacity, but because it lacked coordination discipline.

---

The Capital Illusion

Industrial instinct often responds to congestion with expansion. More laboratories. More suites. More fleet assets. More inventory. More people. More overheads etc.

Our analysis shows that at scale, expansion decisions are frequently triggered by demand volatility and low levels of operational maturity rather than an actual structural shortage. In a non-orchestrated growth scenario, the QC expansion scenario would have been required within two years. With systemic coordination in place, the same network deferred expansion by two to three years. That deferral carries significant strategic value. It preserves capital, improves return on already invested capital, and allows incorporation of technological advances — such as rapid sterility testing or higher levels of automation — into later builds, part of wider long term strategic CAPEX investments. Planned, not rushed.

---

Cold Chain: From Supporting Function to Structural Lever

Cryogenic logistics illustrates the same dynamic. At 10,000 annual batches, shipment volumes approach 400 movements per week. Yes, that is a lot to co-ordinate and plan for! Buffer-based resilience — adding fleet to absorb variability — inflates capital super linearly. Under moderate growth, fleet requirements increased by approximately 15%, hence accompanied by material energy intensity growth (per unit of transport output).

When demand volatility was actively managed through predictive positioning and advanced, proactive slot scheduling, fleet requirements fell by 10–14% without reducing throughput.

Point is, cold chain is no longer a transactional procurement category. It becomes shared industrial infrastructure — and a lever for both cost and sustainability performance.

---

Orchestration and Operational Excellence as Infrastructure

The structural solution however is not just about incremental operational improvements and rushed digital initiatives. That can easily, in practice, manifest as operational firefighting. The required change is architectural, systemic.

For example, let’s take Supply Chain Operations. At industrial scale, autologous networks require a centralised, integrated, yet event-driven Global Supply Chain Control Function (GSCCF) that operates above individual sites and regions. It operates above or in parallel with program leadership, not under.  Its role is not to override regulatory release authority, nor to interfere with GMP execution. Its role is to manage flow, supply continuity and cost control. Business as usual mature supply operations.

As stated, it’s all connected within the operational value chain. Smoothing QC submissions, dynamically rebalancing vector allocation, pacing slot starts, and integrating cryogenic state visibility — effective slot loss can be reduced by several percentage points. In our modelling, that translated into the recovery of hundreds of batches annually without adding physical capacity.

Importantly, orchestration also bridges supply and manufacturing operations with finance. In milestone-based reimbursement environments, QC delays (any operational delay for that matter) directly affect revenue timing and hence working capital exposure. Integrated event-driven visibility enables more disciplined capital and cash management decisions. At industrial scale, operations and market access are structurally intertwined. Differential pricing intensifies the importance of operational discipline further. Premium-priced markets may absorb inefficiency for a time. As mentioned, price-constrained markets might not. In our analysis, the same operational inefficiency that left US margins positive rendered European operations structurally negative. As pricing pressure increases globally, coordination quality will determine geographic viability. Sponsors that industrialise without orchestration risk embedding fragility into their cost base from day one. That’s hard to recover from without potentially serious financial consequences.

---

An Emerging Ecosystem: Supply Chain as a Service (SCaaS)

As throughput increases, logistics providers may evolve beyond shipment execution into integrated orchestration partners. Predictive fleet positioning, event integration and shared performance incentives point toward Supply Chain as a Service (SCaaS) models tailored for advanced therapies. Think about this of highly specialised services going beyond logistics (couriers, packaging, tracking, customs) to a white glove supply chain planning service. This future is closer than we might think. So, which additional parts of your supply operations would you be willing to externalise if the trust is there?

At scale, fragmentation of processes, too many handover points, limited accountability, digital systems and data silos become a strategic liability. Organisations that treat logistics as strategic infrastructure, strategic partnerships, rather than transactional procurement — will gain measurable capital and resilience advantages over the long term.

---

Sustainability in Focus

Industrial-scale CGT manufacturing is inherently energy intensive. Cleanroom environments require continuous HVAC operation to maintain GMP conditions, while cryogenic storage and transportation systems operate continuously to preserve cell viability across the vein-to-vein journey. As programmes scale toward 10,000+ annual batches, these energy demands increase significantly.

What becomes apparent at industrial throughput is that sustainability performance is closely linked to operational efficiency. Idle cleanroom capacity, extended QC waiting times and unnecessary cryogenic holding all increase the energy footprint per batch. In effect, inefficiencies in operational planning translate directly into higher carbon intensity and operating cost.

Consider a simple example. A three-day delay in QC release — which can emerge when utilisation approaches the critical thresholds mentioned above — extends cryogenic storage time across hundreds of batches each week. At industrial scale, this not only drives working capital exposure but also increases energy consumption across cryogenic systems and cleanroom infrastructure. When multiplied across thousands of batches annually, even small coordination inefficiencies can materially increase the environmental footprint of the network.

Conversely, improved operational orchestration reduces both cost and energy intensity. Smoother scheduling across manufacturing suites, better synchronisation between manufacturing and QC release, and predictive cold-chain positioning reduce idle time, avoid unnecessary shipment cycles and limit energy-intensive storage durations.

As advanced therapies industrialise, sustainability therefore becomes less a separate ESG initiative and more an operational design challenge. The same systems that improve throughput stability and cost efficiency also reduce the environmental footprint of the manufacturing network.

Efficiency and sustainability are no longer separate agendas — they are operationally coupled.

---

Transitioning

The transition from specialist to industrial CGT manufacturing is not a simple scaling exercise. It is a systems design and architecture challenge. Probably most important, it’s also people change management. This often is the elephant in the room hindering progress.

Capacity will matter. Automation will matter. Rapid sterility testing will matter. Other emerging initiatives matter. Taken in isolation however and without striving for a solid operational value chain model early in, it can amplify volatility later. At 10,000+ annual batches, orchestration is not merely a digital enhancement, as some might see it. It is structural infrastructure. It is a mindset change. It is operational value by design.

The organisations that recognise this inflection point — and design their operating models accordingly — will define the next era of advanced therapy manufacturing.

Continue the Conversation

The industrialisation of advanced therapies is still in its early stages, and many of the structural challenges explored in this paper will become more visible as programmes approach larger commercial volumes.

If these themes resonate with the challenges your organisation is navigating, or simply you be interested in a deep dive — from manufacturing scale-up to supply chain orchestration or operational value chain design — we welcome the opportunity to exchange perspectives and help.

Radix Partners regularly works alongside therapy developers, CDMO’s, equipment manufacturers and investors to explore scalable operating models for advanced therapies and to identify practical pathways to industrialisation and ops excellence. Our work combines our previous experience as industry SMEs with market research, analytical modelling, operational design and industry insight to help advanced therapy organisations navigate the transition from promising innovation to sustainable industrial operations.

We specialise in operational value chain design for complex life sciences products, with particular emphasis on cell and gene therapy manufacturing ecosystems. Our work supports organisations as they move from clinical phases to commercial readiness and deployment of scalable, resilient operating models capable of sustaining global demand.

What differentiates our approach is a deep integration of strategic, operational and economic perspectives. Rather than addressing manufacturing, supply chain, digital infrastructure or market access in isolation, we focus on how these elements interact across the end-to-end therapy lifecycle. This systems lens allows us to identify structural bottlenecks, model industrial scaling scenarios and design operating models that improve both operational stability and economic performance.

Feel free to reach out for an introduction and a no obligation discussion at any time.

contact@radix.partners                                                              www.radix.partners

Additional research and cross-referencing assumptions was conducted via consulting the following sources: CAR-T Manufacturing and Process Complexity Levine, B. L. et al. (2017). Global Manufacturing of CAR-T Cell Therapy. Molecular Therapy. Manufacturing Duration and Operational Constraints Tyagarajan, S., Spencer, T., & Smith, J. (2020). Optimizing CAR-T Manufacturing Processes. Sterility Testing Constraints Pharmaceutical Technology (2024). Rapid Sterility Methods for CAR-T Therapies. Supply Chain and Commercialisation Models Lam, C. (2021). Model-Based Approaches to Commercialisation of Autologous Cell Therapies. Industry Scaling Examples Legend Biotech manufacturing capacity disclosures. Industry analysis of CAR-T manufacturing expansion.